Sio Gene Therapies Inc. buy tamam
Start price
31.08.17
/
50%
€143.67
Target price
09.01.18
€144.32
Performance (%)
-88.37%
End price
09.01.18
€16.71
Summary
This prediction ended on 09.01.18 with a price of €16.71. The BUY prediction by tamam for Sio Gene Therapies Inc. performed very badly with a performance of -88.37%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sio Gene Therapies Inc. | - | - | - | - |
| iShares Core DAX® | 3.002% | 3.742% | 24.169% | 65.664% |
| iShares Nasdaq 100 | 2.966% | 1.308% | 9.141% | 111.170% |
| iShares Nikkei 225® | 5.606% | 4.472% | 21.237% | 55.883% |
| iShares S&P 500 | 2.312% | 1.880% | 6.333% | 67.956% |
Comments by tamam for this prediction
In the thread Sio Gene Therapies Inc. diskutieren
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
One of the most watched trial results on the horizon is for Intepirdine targeting Alzheimers'. Phase 3 data is out from Axovant Sciences by the end of September. Positive results would trigger a massive rally in the stock. I am not sanguine simply because this disease area has the highest failure rate in the industry.
(Vom Mitglied beendet)